Inizio

Inizio operates as a specialised B2B platform for health and life sciences companies. It creates value by combining domain expertise, delivery teams, proprietary data assets and software products to support commercialisation, medical affairs, launch execution and stakeholder engagement. The model is built around long-cycle enterprise relationships where consulting and managed services open the door to wider deployment of analytics, data products and software across multiple functions.

Inizio is a private equity-backed life sciences commercialisation group that combines consulting, medical affairs services, healthcare marketing, field engagement and proprietary software. Its offering spans advisory and transformation work, scientific communications, commercial execution, benchmarking data and AI-enabled decision support products used across portfolio strategy, launch planning, medical affairs and omnichannel engagement.

The company makes money primarily from enterprise service contracts, consulting retainers and managed programmes sold to pharmaceutical and biotechnology companies. It also appears to generate software and data revenue from proprietary platforms and benchmarking assets, often embedded into broader client engagements. Its customers are business buyers inside pharma and biotech organisations rather than consumers.